TO THE EDITOR
Analysis of the ordered rearrangement of V, D, and J genes allows the precise determination of the developmental stage of both normal and malignant lymphocytes. We performed this analysis in clonal B-cell tumors that arise rapidly in transgenic mice, which we engineered to express c-MYC under the control of mouse immunoglobulin kappa (IgK) light-chain gene-regulatory elements (Figure 1a) . We report the case of a pro-B-cell tumor where clonally related B cells were detected, which unexpectedly harbored different V genes rearranged in frame to the clonal DJ rearrangement.
Two transgenic founders were generated ( Figure 1b , left panel), both of which succumbed at 8 weeks of age to pronounced lymphosplenomegaly with histologically a 'starry sky' landscape reminiscent of human Burkitt's lymphoma (data not shown). Immunohistochemical and flow cytometric analysis confirmed that the tumors were of B-cell lineage (as determined by CD19 and B220 staining, data not shown). The expression of transgenic RNA was detected in tumor tissue by Northern blot (Figure 1b , right panels). , and mouse #20 (T20) tumors, wild-type tail (t); pX is phiX ladder, and w is water control. Lower panel: control PCR (p53). PCR products were subcloned and sequenced. In all, 10 out of 10 clones showed identical DSP2.9-Jh3 rearrangement (shown at the bottom). To establish clonality, V-less D-Jh4 segments at the Ig heavychain locus were first amplified by PCR using a strategy similar to previously described. 1 According to this analysis, the tumor in mouse #3 was most likely monoclonal ( Figure 1c, T3 lanes) . Its D-Jh4 segment was subcloned, and the same DSP2.9-Jh3 rearrangement was found in 10/10 sequenced clones (Figure 1c, bottom) . Thus, most likely, this tumor carries a VDJ rearrangement on one allele and DSP2.9-Jh3 on the other. Supporting this result, Southern blots were performed (Figure 1d ), which confirmed that tumor #3 was clonal and carried biallelic heavy-chain gene rearrangements. Curiously, the signal intensity for the predicted DSP2.9-Jh3-rearranged allele (based on the DSP2.9-Jh3 restriction map, which was reconstructed in silico from NCBI contigs, data not shown) was reduced compared to the other allele in lymph node DNA. This suggested that further rearrangements may be occurring at the DSP2.9-Jh3 allele.
The DSP2.9-Jh3 signature could either signify that the tumor is a pro-B-cell tumor with DJ rearranged on both alleles or a later stage tumor with VDJ at one allele and DSP2.9-Jh3 at the other. To investigate this, PCRs for completed VDJ rearrangements were performed. Combined and degenerate 3 0 -end panV genes primers were employed as described previously. 2 Sequences of the subcloned PCR products displayed the same DSP2.9-Jh3 rearrangement in 14 out of 20 clones (Figure 2a ). DSP2.9-Jh3 clones displayed different V gene usage and loss of 0, 3, 6, or 9 nucleotides at the V-DJ joints, indicating that the tumor clone was not arrested in development, but could progress and diverge by recombining distinct V genes at its DSP2.9-Jh3 allele. Furthermore, the nonrandom, in-frame loss of nucleotides at the V-DJ joints strongly suggested positive selection of those cells expressing a functional B-cell receptor (or negative selection of those clones that were out of frame; Figure 3 ).
To support this view, we searched for IgM transcripts carrying the clonal signature by RT-PCR on tumor RNA, using panV forward and Cm reverse primers. Indeed, sequences harboring the clonal signature were found in abundance (11 out of 20 sequences, Figure 2b ) and obeyed the same joining properties observed in Figure 2a . In agreement with this observation, populations of IgM-and IgK-expressing cells (6.6 and 5.7% of total cells, respectively) were detected in the tumor by flow cytometry (data not shown).
Finally, a primer was designed in the intron preceding DSP2.9 and used in combination with a reverse Cm primer to look for Dm transcripts. Five out of six sequences contained DSP2.9-Jh3. Interestingly, these transcripts encoded for putative proteins similar, at their 5 0 end, to the previously described Dm proteins, but different at their 3 0 portion owing to a frame shift. In addition, differential splicing of these transcripts from Jh3 to Cm resulted in the coding of two never before reported proteins of 65 (DSP2.9-Jh3-65; GenBank: AY769939) and 100 (DSP2.9-Jh3-100; GenBank: AY769940) amino acids of length. Figure 3 summarizes our model, where the tumor clone has VDJ rearranged at the one allele (not shown), with V-unrearranged DSP2.9-Jh3 at the other, and tries to undergo V-DJ at the latter to rescue the unproductive first allele. Successful in-frame rearrangement is required for the resulting clone to be positively selected, while unproductive rearrangements are either not positively selected or deleted.
Unlike most tumor types, clonality and development can be investigated in B-cell tumors owing to the unique DNA rearrangements that physiologically occur in lymphocytes, and which irreversibly mark the genealogy of each cell. With this regard, mouse B-cell tumors offer two major advantages over humans: (a) easy accessibility to all lymphohematopoietic tissues for sampling (which should facilitate the identification of the cell and organ site of tumor origin); and (b) the availability of the complete genomic sequence of the Ig loci (at least for the C57BL/6 strain). We took advantage of these peculiarities to investigate clonality and development in murine tumors resulting from enforced expression of c-MYC in B cells. Herein, we report novel findings resulting from detailed molecular analysis of one such tumor. We performed Southern blots for Ig heavy-chain gene rearrangement to determine clonality and we compared DNA from two organs: while two rearranged bands of comparable intensity were detected in spleen, one was weaker in lymph node. Additional faint clonal bands were also observed in the tumor but not in control tail DNA (Figure 1d ). PanD-Jh4 PCR allowed the identification of a V-less DJ rearrangement (DSP2.9-Jh3) that upon reconstruction in silico we could attribute to the fainter allele. In the attempt to understand the genesis of the fainter allele in the lymph node, we PCR amplified and sequenced for complete VDJ: DSP2.9-Jh3 was frequent, distinct V genes were recombined to it, and the joints were in frame (Figure 2a) . That all rearrangements were in frame was surprising and suggested positive selection for those clones expressing the Ig on the surface, as is the case for normal B cells. Consistent with this, V-DSP2.9-Jh3-Cm transcripts were found (Figure 2b) . Thus, enforced expression of transgenic c-MYC was not sufficient to halt all transformed cells at a certain developmental stage, and cells that were able to proceed in development were still subject to rules governing normal B-cell differentiation.
Although widely considered clonal diseases, originating from a single tumor stem cell, 3, 4 heavy-chain studies of human B-cell leukemias and lymphomas have revealed oligoclonality in a percentage of cases. 5, 6 Furthermore, examples of clonal evolution with disease progression, 7 or upon culturing of leukemic cells in vitro, 8 have also been described. The case we report here, in a mouse tumor, is in line with these human reports, but adds to the story: under the pressure of growing in vivo, we show that tumor cells are not frozen in development, but can proceed while still obeying to rules governing normal B-cell differentiation, despite malignant transformation.
Figure 3
Model. Maintained rules of development. DJ-rearranged tumor stem cells can proceed and diverge in development by acquiring distinct V genes. Selection is in place and favors in-frame rearrangements. Out-of-frame rearrangements are either not positively selected or deleted.
